The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci (VRE) infection or colonization. The invention provides for a method for reducing the risk of VRE infection/colonization in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising at least one of a Clostridium scindens and/or a Blautia producta in a formulation suitable for administration to the subject. The present invention also provides for a method of diagnosing a subject with a VRE infection/colonization, or at risk for VRE infection/colonization. The present invention also provides for a kit comprising the therapeutic composition described herein.
